Loading...
•
Dec 31, 2022
LivaNova Q4 2022 Earnings Report
LivaNova's Q4 2022 performance reflected revenue growth across all regions, driven by Cardiopulmonary and Neuromodulation business units, with GAAP EPS of $0.03 and adjusted EPS of $0.81.
Key Takeaways
LivaNova PLC reported a 1.8% increase in fourth-quarter revenue, reaching $274.9 million, and a U.S. GAAP diluted earnings per share of $0.03. The company experienced growth across all regions, particularly in the Cardiopulmonary and Neuromodulation business units. Adjusted diluted earnings per share were $0.81.
Fourth-quarter revenue increased 1.8% on a reported basis and 6.2% on a constant-currency basis.
U.S. GAAP diluted earnings per share was $0.03 and adjusted diluted earnings per share was $0.81.
Completed first clinical cases using EssenzTM at two major centers in Europe.
Received ECMO indication 510(k) clearance for LifeSPARCTM.
Revenue by Segment
Forward Guidance
LivaNova expects revenue for full-year 2023 to grow between 3 and 5 percent on a constant-currency basis. Adjusted diluted earnings per share for 2023 are expected to be in the range of $2.45 to $2.65, assuming a share count of 54 million for full-year 2023. In 2023, the Company estimates that adjusted free cash flow will be in the range of $80 to $100 million.
Positive Outlook
- Revenue for full-year 2023 to grow between 3 and 5 percent on a constant-currency basis.
- Foreign currency is expected to be a 1 percent tailwind.
- Adjusted diluted earnings per share for 2023 are expected to be in the range of $2.45 to $2.65.
- Share count of 54 million for full-year 2023.
- Adjusted free cash flow will be in the range of $80 to $100 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...